Monopar Therapeutics MNPR 深 沪
等待开盘 08-20 09:30:00 美东时间
123.84
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 123.84
- 总市值 8.31亿
- 52周最高 124.82
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 32.77
- 委 比 0.00%
- 总股本 671.22万
- 历史最高 240.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.3695
- 每 手 1
- 风险率 20.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Monopar cut to Neutral at Cantor on valuation
Monopar Therapeutics (MNPR) traded lower on Thursday after Cantor Fitzgerald downgraded the clinical-stage biopharma to Neutral from Overweight, arguing that the stock is fairly valued at current leve...
08-14 01:11
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Cantor Fitzgerald analyst Kristen Kluska downgraded Monopar Therapeutics Inc (NASDAQ:MNPR) from O...
08-14 00:09
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
08-13 03:48
Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.71 percent. This is a 77.14 percent decrease over losses of $(0.35) per share from the same period last year.
08-12 21:32
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics announced second quarter 2026 financial results and updates on ALXN1840 for Wilson Disease. The company initiated a rolling NDA submission for ALXN1840, received Rare Pediatric Disease (RPD) designation, and presented positive Phase 3 and Phase 2 clinical data. Financially, the company reported a net loss of $5.3 million and increased R&D and G&A expenses. Cash reserves of $134.3 million are expected to support operations thr...
08-12 13:30
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease
The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections. Monopar has submitted the first completed sections of the NDA. If the completed NDA is accepted for fil...
07-22 20:02
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Monopar Therapeutics Inc. has appointed seasoned commercial leaders to support the anticipated launch of its first product, ALXN1840, for Wilson disease, pending FDA approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, has joined the Board of Directors. Sharon Funk and Daniel Olmstead have been appointed as Senior Vice Presidents for Sales and Marketing, and Market Access, Distribution, and Patient Services, respe...
07-20 12:00
